Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.
Photys Therapeutics has raised $75.0M in total funding. The most recent round was Series A. The last funding was announced in September 2022.
Photys Therapeutics's investors include 8VC, Longwood Fund, Omega Funds, Ono Venture Investment, MPM Capital.
Photys Therapeutics is headquartered in Cambridge, United States.
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.
Photys Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Photys Therapeutics — Funding & Investors." VCBacked, September 8, 2022, https://www.vcbacked.co/company/photys-therapeutics. Accessed July 19, 2026.
VCBacked. (2022). Photys Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/photys-therapeutics
{{cite web |title=Photys Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/photys-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated